Clinical Trial Update: Pembrolizumab Plus Chemotherapy in NSCLC With Targetable Genetic Alterations After Progression on Targeted Agents [Phase 2]

View source ↗

Summary

Phase 2 trial results for pembrolizumab plus chemotherapy in non-small cell lung cancer with targetable genetic alterations after progression on targeted therap…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Pembrolizumab (pembrolizumab)

Snippet

Sponsor: University of Michigan Rogel Cancer Center | Conditions: Non-small Cell Lung Cancer | Phase 2 | Status: COMPLETED | Results posted: 2025-05-30